Sponsored by:

Molecular Imaging: Page 96

Novartis touts prostate cancer study results at ASCO 2021
By AuntMinnie.com staff writers
Novartis highlighted results presented at the virtual American Society of Clinical Oncology meeting that suggest lutetium-177 prostate-specific membrane antigen-617 is safe and effective for patients with PSMA-positive metastatic prostate cancer.
June 7, 2021
2019 04 17 20 48 2514 Prostate 3 D 400
Physicists want ban on radioactive alternative medicine pendants
By Will Morton
A group of Malaysian physicists are recommending a ban on so-called "scalar energy" pendants after finding that the alternative medicine trinkets are actually embedded with radioactive isotopes, according to a study published June 1 in Plos One.
June 6, 2021
2021 06 04 23 05 0446 2021 06 07 Radioactive Pendants 20210604234226
SNMMI offers letter to contest SPECT/CT denials
By AuntMinnie.com staff writers
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published a letter template for healthcare providers to use to contest coverage denials of SPECT/CT exams.
June 2, 2021
2018 05 22 18 57 9927 Snmmi Logo 400
ImaginAb lands $13M in growth funding
By AuntMinnie.com staff writers
Radiopharmaceutical developer ImaginAb has raised almost $13 million in funding to support the company's growth and further development of its CD8 Immuno-PET agent.
June 2, 2021
2020 08 07 21 29 1304 Radiotherapy2 400
Blue Earth points to Axumin studies at ASCO meeting
By AuntMinnie.com staff writers
Bracco molecular imaging subsidiary Blue Earth Diagnostics announced that several abstracts evaluating its PET radiotracer Axumin (fluciclovine F-18) for imaging men with suspected prostate cancer will be presented June 4 at the 2021 American Society of Clinical Oncology (ASCO) virtual annual meeting.
June 2, 2021
2021 01 16 00 14 5464 Prostate Cancer 400
Fusion Pharmaceuticals to build radiopharma plant in Canada
By AuntMinnie.com staff writers
McMaster University spin-off company Fusion Pharmaceuticals announced it has entered a 15-year lease agreement with the school for a new manufacturing facility for therapeutic pharmaceuticals near its campus in Hamilton, Ontario.
June 2, 2021
2019 02 12 23 11 2325 Canada Flag 400
GenesisCare among early providers to offer Pylarify
By AuntMinnie.com staff writers
Lantheus Medical Imaging has announced that oncology provider GenesisCare will be the first to administer commercially available doses of its Pylarify PET radiopharmaceutical, which was approved last month.
June 2, 2021
2021 01 12 22 13 6193 Immunotherapy T Cell Fluorescence 400
Choline-PET/CT offers best imaging for hyperparathyroidism
By Will Morton
Choline-PET/CT should be the imaging tool of choice for localization of primary hyperparathyroidism in patients prior to surgery, according to research published June 3 in JAMA Otolaryngology -- Head and Neck Surgery.
June 2, 2021
2021 06 02 22 17 8771 Parathyroid Glands 400
'Early frame' PET may reduce cost and burden in Alzheimer's disease
By Will Morton
PET imaging of patients to detect Alzheimer's disease may be effective in minutes rather than hours after they are injected with a radiotracer, according to research published May 28 in the Journal of Nuclear Medicine. The finding suggests "early frame" PET may reduce imaging costs and burden on patients and their families.
June 1, 2021
2021 06 01 21 39 9668 2021 06 02 Early Pet For Ad Ef Ap Image 400
Blue Earth touts Axumin results in Lancet
By AuntMinnie.com staff writers
Bracco molecular imaging subsidiary Blue Earth Diagnostics is highlighting results of a study published in Lancet showing that postprostatectomy radiation therapy guided by the company's PET radiotracer Axumin (fluciclovine F-18) helped increase biochemical event-free survival rates in men with recurrent prostate cancer.
May 26, 2021
2019 04 17 20 48 2514 Prostate 3 D 400
Lantheus gets FDA nod for Pylarify PET agent for prostate cancer
By Brian Casey
Lantheus Medical Imaging has received approval from the U.S. Food and Drug Administration (FDA) for Pylarify (F-18 DCFPyL), a PET radiopharmaceutical designed to target prostate-specific membrane antigen.
May 26, 2021
2021 05 27 15 28 4419 2021 05 27 Pylarify Image Aunt Minnie pptx 400
PET/MRI advances efforts for virtual biopsy in breast cancer
By Will Morton
FDG-PET/MRI combined with ultrasound could reduce the need for invasive biopsy to confirm suspicious findings in women with newly diagnosed metastatic breast cancer, according to a study by German researchers published May 20 in the Journal of Nuclear Medicine.
May 25, 2021
2021 05 26 19 12 3151 2021 05 26 Fdg Pet Mri Vs Us Mri 20210526194155
Previous Page
Page 96 of 614
Next Page